BRPI0607092A2 - polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende - Google Patents

polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende

Info

Publication number
BRPI0607092A2
BRPI0607092A2 BRPI0607092-2A BRPI0607092A BRPI0607092A2 BR PI0607092 A2 BRPI0607092 A2 BR PI0607092A2 BR PI0607092 A BRPI0607092 A BR PI0607092A BR PI0607092 A2 BRPI0607092 A2 BR PI0607092A2
Authority
BR
Brazil
Prior art keywords
polymorph
crystalline
amino
methyl
hydroxypropane
Prior art date
Application number
BRPI0607092-2A
Other languages
English (en)
Inventor
Uwe Eiermann
Bernd Junghans
Tim Sattelkau
Bernhard Knipp
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36090730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607092(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0607092A2 publication Critical patent/BRPI0607092A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

POLIMORFO CRISTALINO DE MONOIDRATO DE SAL MONOSSóDICO DE áCIDO 3- (N-METIL-N-PENTIL) AMINO-1-HIDROXIPROPANO-1, 1-DIFOSFÈNICO,IBANDRONATO CRISTALINO, E COMPOSIçãO FARMACêUTICA QUE O COMPREENDE. Refere-se a presente invenção a uma nova forma de cristal polimorfo de monoidrato de sal monossódico de ácido 3-(N-metil-N'-pentil) amino-1-hidroxi-propano-l,1-difosfânico (Ibandronato) com a fórmula (1)
BRPI0607092-2A 2005-02-01 2006-01-24 polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende BRPI0607092A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100686 2005-02-01
PCT/EP2006/000580 WO2006081963A1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph a

Publications (1)

Publication Number Publication Date
BRPI0607092A2 true BRPI0607092A2 (pt) 2009-08-04

Family

ID=36090730

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607092-2A BRPI0607092A2 (pt) 2005-02-01 2006-01-24 polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende

Country Status (25)

Country Link
US (1) US7714158B2 (pt)
EP (2) EP1848728B1 (pt)
JP (2) JP5828608B2 (pt)
KR (1) KR100908529B1 (pt)
CN (1) CN101111504B (pt)
AR (1) AR053012A1 (pt)
AU (1) AU2006210009B2 (pt)
BR (1) BRPI0607092A2 (pt)
CA (1) CA2594802C (pt)
CY (1) CY1121703T1 (pt)
DK (1) DK2662380T3 (pt)
ES (2) ES2478302T3 (pt)
HU (1) HUE042316T2 (pt)
IL (1) IL184562A (pt)
LT (1) LT2662380T (pt)
MX (1) MX2007009107A (pt)
NO (1) NO20073723L (pt)
PL (1) PL2662380T3 (pt)
PT (1) PT2662380T (pt)
RU (1) RU2368617C2 (pt)
SI (1) SI2662380T1 (pt)
TR (1) TR201902609T4 (pt)
TW (1) TWI374889B (pt)
WO (1) WO2006081963A1 (pt)
ZA (1) ZA200706168B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
WO2006081962A1 (en) * 2005-02-01 2006-08-10 F.Hoffmann-La Roche Ag Ibandronate polymorph b
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
AU2007270897A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
US20090012047A1 (en) * 2006-11-16 2009-01-08 Eran Turgeman Crystalline forms of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
AU2008238058B2 (en) * 2007-04-11 2010-12-02 F. Hoffmann-La Roche Ag Multi step synthesis of ibandronate
EP2316841A1 (en) 2007-04-19 2011-05-04 Dr. Reddy's Laboratories Limited Ibandronate sodium polymorphs
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (pt) * 1988-11-28 1993-01-11 Ciba Geigy Ag
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
ATE239032T1 (de) 1998-10-16 2003-05-15 Akzo Nobel Nv (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17- pregn-5-(10)-en-20-yn-3-on als reine verbindung
BR9915927A (pt) 1998-12-04 2001-08-21 Roche Diagnostics Gmbh Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
CN1939314A (zh) 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
SI1596870T2 (sl) 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
DE202005021414U1 (de) * 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium

Also Published As

Publication number Publication date
AU2006210009A1 (en) 2006-08-10
CA2594802C (en) 2012-11-27
SI2662380T1 (sl) 2019-04-30
AR053012A1 (es) 2007-04-18
ZA200706168B (en) 2008-09-25
IL184562A0 (en) 2007-10-31
HUE042316T2 (hu) 2019-06-28
TR201902609T4 (tr) 2019-03-21
WO2006081963A1 (en) 2006-08-10
ES2712644T3 (es) 2019-05-14
US20060172975A1 (en) 2006-08-03
RU2368617C2 (ru) 2009-09-27
JP2015205907A (ja) 2015-11-19
US7714158B2 (en) 2010-05-11
JP5828608B2 (ja) 2015-12-09
CN101111504B (zh) 2011-12-21
CA2594802A1 (en) 2006-08-10
IL184562A (en) 2015-11-30
NO20073723L (no) 2007-08-28
TWI374889B (en) 2012-10-21
TW200638939A (en) 2006-11-16
EP1848728B1 (en) 2014-06-11
EP2662380B1 (en) 2018-11-21
ES2478302T3 (es) 2014-07-21
EP2662380A1 (en) 2013-11-13
MX2007009107A (es) 2007-09-11
RU2007132701A (ru) 2009-03-10
KR20070100394A (ko) 2007-10-10
EP1848728A1 (en) 2007-10-31
LT2662380T (lt) 2019-03-12
JP6039754B2 (ja) 2016-12-07
PT2662380T (pt) 2019-02-27
DK2662380T3 (en) 2019-03-18
PL2662380T3 (pl) 2019-05-31
JP2008529980A (ja) 2008-08-07
CN101111504A (zh) 2008-01-23
AU2006210009B2 (en) 2009-08-13
CY1121703T1 (el) 2020-07-31
KR100908529B1 (ko) 2009-07-20

Similar Documents

Publication Publication Date Title
CY1121703T1 (el) Ιατρικη χρηση του πολυμορφου a toy ibanδρονικου
IL182690A0 (en) Process for the preparation of ibandronate
BRPI0607093A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
IL172513A0 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
AR059916A1 (es) Procesos y productos intermedios para preparar compuestos esterico
BRPI0500393B8 (pt) forma cristalina ii de agomelatina e sua composição farmacêutica
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BR112014014148A2 (pt) misturas de ácidos difosfínicos e dialquilfosfínicos, processo para produção das mesmas e uso das mesmas
DOP2009000130A (es) Sal de potasio cristalina de analogos de lipoxina a4
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
MX359363B (es) Dihidroetorfina y su preparacion.
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
ECSP099045A (es) Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido
ES2324015T1 (es) Proceso de sintesis de acidos bisfosfonicos geminales o de sus sales farmaceuticamente aceptables o de sus hidratos.
BR112012027623A2 (pt) processo para a produção de sais de ralfinamida metanossulfonato ou seus r-enantiômeros
WO2007013097A8 (en) Improved process for the preparation of ibandronate sodium
WO2007074475A3 (en) Novel polymorphic forms of ibandronate
WO2007083243A3 (en) An improved process for the preparation of risedronate sodium hemi-pentahydrate
MX2009010850A (es) Sintesis de ibandronato en multiples etapas.
WO2010086700A3 (en) An improved process for the preparation of choline salt of fenofibric acid and its novel polymorph
TH84983B (th) พหุสัณฐานไดแบนโดรเนท b
DE602006005488D1 (de) Verfahren zur herstellung von losartanderivaten durch chlorierung und reduktion der entsprechenden 1h-imidazol-5-carbaldehyde
ECSP099267A (es) Formas de sal de compuestos de benzotienilo sustituidos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI